Affimed Therapeutics

NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.

Launch date

2000

Employees

Market cap

Enterprise valuation

€36m (Public information from Sep 2024)

Company register number HRB 721206 (Mannheim)

Heidelberg Baden-Württemberg (HQ)

http://affimed.com

https://twitter.com/affimity https://www.linkedin.com/company/affimed-ag

View job openings

Revenues, earnings & profits over time

EUR	2019	2020	2021	2022	2023	2024	2025
Revenues	21.4m	28.4m	40.4m	41.4m	8.3m	5.0m	6.8m
% growth	(16 %)	33 %	42 %	2 %	(80 %)	(40 %)	36 %
EBITDA	(31.0m)	(34.2m)	(64.0m)	(86.6m)	(104m)	-	-
% EBITDA margin	(145 %)	(121 %)	(159 %)	(210 %)	(1255 %)	-	-
Profit	(32.4m)	(41.4m)	(57.5m)	(86.0m)	(106m)	-	-
% profit margin	(151 %)	(146 %)	(143 %)	(208 %)	(1280 %)	-	-
R&D budget	43.8m	50.0m	81.5m	98.8m	95.0m	-	-
R&D % of revenue	205 %	176 %	202 %	239 %	1148 %	-	-

Date	Investors	Amount	Round
Apr 2007	BioMed Partners EQT Life Sciences OrbiMed	$32.0m	Series B
Apr 2010	BioMed Partners Novo Nordisk Calibrium	€20.0m	Series C
Oct 2012	Calibrium	€15.5m	Series D
Sep 2014	Perceptive Advisors	$14.0m	Debt
Sep 2014	BioMed Partners EQT Life Sciences Calibrium	$15.7m	Series E
Sep 2014	N/A	$56.0m	IPO
May 2015	N/A	$37.1m	Post IPO Equity
Oct 2015	Calibrium	€19.1m	Post IPO Equity
Jan 2017	N/A	$16.6m	Post IPO Equity
Aug 2018	Roche	$96.0m	Post IPO Equity
Jan 2020	New Enterprise Associates	N/A	-
Jan 2021	N/A	$115m	Post IPO Equity
Apr 2022*	N/A	$90.0m	Post IPO Equity
Total Funding		€78.9m

Tech stackLearn more about the technologies and tools that this company uses.